Related Experiment Video
Updated: May 22, 2026
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
Published on: October 26, 2017
[Serum miR-103 as a potential diagnostic biomarker for breast cancer]
Xiaopai Wang1, Xingping Wu, Lixu Yan
1Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, China. wangxiaopai86@163.com
Objective:
To evaluate the diagnostic value of serum miR-103 for breast cancer and its correlation to the clinicopathological features of the patients.
Methods:
We collected the serum samples and corresponding formalin-fixed paraffin-embedded (FFPE) surgical specimens from 50 breast cancer patients, using the serum samples from 50 healthy women as the control. The total RNA was extracted from the samples for quantitative analysis of miR-103 using real-time RT-PCR.
Results:
The serum levels of miR-103 expression were significantly higher in the cancer patients than in the healthy control group (P<0.01). In the cancer patients, high miR-103 expression was significantly correlated to advanced clinical stage (P<0.05) and lymph node metastasis (P<0.05). miR-103 showed a receiver operating characteristic (ROC) curve area of 84.3%, and a sensitivity of 84% and a specificity of 70% in discriminating breast cancer patients from the control subjects.
Conclusion:
Serum miR-103 can serve as a potential diagnostic marker for breast cancer and provides useful information of the clinicopathological features of the patients.
